These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 21839027)

  • 1. The von Willebrand factor from basic mechanisms to clinical practice.
    Federici AB
    Blood Transfus; 2011 May; 9 Suppl 2(Suppl 2):s1-2. PubMed ID: 21839027
    [No Abstract]   [Full Text] [Related]  

  • 2. Human plasma von Willebrand factor/factor VIII complex (Haemate P/Humate-P) in von Willebrand disease and haemophilia A: a viewpoint by Eric Berntorp.
    Berntorp E
    Drugs; 2007; 67(10):1520. PubMed ID: 17600396
    [No Abstract]   [Full Text] [Related]  

  • 3. Prospective, observational study of plasma-derived factor VIII/von Willebrand factor in immune tolerance induction: the PRISM registry.
    Kruse-Jarres R; Gilsenan A; Spears J; Kaye JA
    Haemophilia; 2015 Mar; 21(2):e122-e124. PubMed ID: 25623889
    [No Abstract]   [Full Text] [Related]  

  • 4. Von Willebrand factor in high-purity factor VIII complex concentrates: chaperone protein or key to therapies? A meeting report.
    Federici AB; Mannucci PM; Marco P
    Haemophilia; 2008 Jan; 14(1):133-9. PubMed ID: 17941830
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of von Willebrand Factor Concentrate in Inherited von Willebrand Disease: How Often Is It Useful to Add Factor VIII?
    Drillaud N; Ardillon L; Ternisien C; Valentin JB; Fouassier M; Gillet B; Gruel Y; Sigaud M; Horvais V; Bene MC; Trossaërt M
    Transfus Med Rev; 2020 Apr; 34(2):128-129. PubMed ID: 31813707
    [No Abstract]   [Full Text] [Related]  

  • 6. Management of bleeding disorders in adults.
    Peyvandi F; Klamroth R; Carcao M; Federici AB; DI Minno G; Jiménez-Yuste V; Rodriguez Merchán EC
    Haemophilia; 2012 May; 18 Suppl 2():24-36. PubMed ID: 22530576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. von Willebrand disease: treatment with or without factor VIII?
    Konkle BA
    J Thromb Haemost; 2007 Jun; 5(6):1113-4. PubMed ID: 17590904
    [No Abstract]   [Full Text] [Related]  

  • 8. New treatment for von Willebrand disease.
    Belavic JM
    Nurse Pract; 2010 Sep; 35(9):13-4. PubMed ID: 20720463
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetic profile of Optivate® (high-purity factor VIII/von Willebrand factor concentrate) in treating von Willebrand disease.
    Shaikh-Zaidi R; Lubetsky A; Inbal A; Dash C
    Haemophilia; 2016 Jan; 22(1):e64-7. PubMed ID: 26572507
    [No Abstract]   [Full Text] [Related]  

  • 10. Von Willebrand disease.
    Berntorp E
    Pediatr Blood Cancer; 2013; 60 Suppl 1():S34-6. PubMed ID: 23109385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of von Willebrand disease with FVIII/VWF concentrates.
    Castaman G
    Blood Transfus; 2011 May; 9 Suppl 2(Suppl 2):s9-13. PubMed ID: 21839030
    [No Abstract]   [Full Text] [Related]  

  • 12. Update on the management of von Willebrand disease.
    Federici AB
    Clin Adv Hematol Oncol; 2008 Jan; 6(1):29-30. PubMed ID: 18322438
    [No Abstract]   [Full Text] [Related]  

  • 13. Recombinant von Willebrand factor.
    Schwarz HP; Turecek PL; Pichler L; Mitterer A; Mundt W; Dorner F; Roussi J; Drouet L
    Thromb Haemost; 1997 Jul; 78(1):571-6. PubMed ID: 9198218
    [No Abstract]   [Full Text] [Related]  

  • 14. Von Willebrand factor, factor VIII and the factor VIII/von Willebrand factor complex.
    Ingerslev J
    Dan Med Bull; 1990 Oct; 37(5):385-406. PubMed ID: 2125548
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibitor development in haemophilia A: the role of von Willebrand factor/factor VIII concentrates.
    Goudemand J
    Haemophilia; 2007 Dec; 13 Suppl 5():47-51. PubMed ID: 18078397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A von Willebrand factor/factor VIII complex restores platelet adhesion and fibrin formation in type 3 von Willebrand syndrome.
    Arderiu G; Díaz-Ricart M; Aznar-Salatti J; Escolar G; Ordinas A
    J Thromb Haemost; 2003 Apr; 1(4):865-6. PubMed ID: 12871435
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhibitors in haemophilia A: the role of VWF/FVIII concentrates--a meeting report.
    Kaveri S; Gringeri A; Heisel-Kurth M; Kreuz W
    Haemophilia; 2009 Mar; 15(2):587-91. PubMed ID: 19347997
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of factor VIII/von Willebrand factor concentrate Alphanate in preventing excessive bleeding during surgery in subjects with von Willebrand disease.
    Rivard GE; Aledort L;
    Haemophilia; 2008 Mar; 14(2):271-5. PubMed ID: 18194310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical overview of Fanhdi/Alphanate (plasma-derived, VWF-containing FVIII concentrate) in immune tolerance induction in haemophilia A patients with inhibitors.
    Jiménez-Yuste V; Oldenburg J; Rangarajan S; Kurth MH; Bozzo J; Santagostino E
    Haemophilia; 2016 Jan; 22(1):e71-4. PubMed ID: 26612826
    [No Abstract]   [Full Text] [Related]  

  • 20. The factor VIII/von Willebrand factor complex: basic and clinical issues.
    Federici AB
    Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.